Abbott Laboratories [NYSE: ABT] slipped around -2.77 points on Tuesday, while shares priced at $99.98 at the close of the session, down -2.70%. The company report on March 7, 2023 that Abbott Receives FDA Clearance for First Commercially Available Lab-based Blood Test to Help Evaluate Concussion.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
New test will run on Abbott’s Alinity® i laboratory instrument, complementing Abbott’s rapid i-STAT TBI Plasma test, cleared by the FDA in 2021.
Given the significant number of Alinity i instruments in use in labs across the U.S., Abbott’s lab test will make concussion testing available to more people across the country.
Abbott Laboratories stock is now -8.94% down from its year-to-date (YTD) trading value. ABT Stock saw the intraday high of $103.10 and lowest of $99.82 per share. The company’s 52-week high price is 124.36, which means current price is +0.32% above from all time high which was touched on 01/11/23.
Compared to the average trading volume of 4.73M shares, ABT reached a trading volume of 6303268 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Abbott Laboratories [ABT]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $123.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 26, 2022. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on October 18, 2022, representing the official price target for Abbott Laboratories stock. Previously, the target price had yet another raise to $110, while Jefferies analysts kept a Hold rating on ABT stock.
The Average True Range (ATR) for Abbott Laboratories is set at 2.18, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 3.91. The Price to Book ratio for the last quarter was 4.75, with the Price to Cash per share for the same quarter was set at 5.96. Price to Free Cash Flow for ABT in the course of the last twelve months was 37.98 with Quick ratio for the last quarter at 1.20.
How has ABT stock performed recently?
Abbott Laboratories [ABT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.71. With this latest performance, ABT shares dropped by -10.56% in over the last four-week period, additionally sinking by -2.46% over the last 6 months – not to mention a drop of -17.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 34.92, with the RSI for the last a single of trading hit 33.74, and the three-weeks RSI is set at 37.19 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 108.63, while it was recorded at 102.13 for the last single week of trading, and 106.69 for the last 200 days.
Abbott Laboratories [ABT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of +19.16 and a Gross Margin at +51.14. Abbott Laboratories’s Net Margin is presently recorded at +15.82.
Return on Equity for this stock inclined to 19.05, with Return on Assets sitting at 9.23.
Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.60.
Earnings analysis for Abbott Laboratories [ABT]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 8.30%.
Insider trade positions for Abbott Laboratories [ABT]
There are presently around $130,670 million, or 76.20% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 155,480,794, which is approximately 0.594% of the company’s market cap and around 0.40% of the total institutional ownership; BLACKROCK INC., holding 137,935,172 shares of the stock with an approximate value of $13.79 billion in ABT stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $7.68 billion in ABT stock with ownership of nearly -2.565% of the company’s market capitalization.
Positions in Abbott Laboratories stocks held by institutional investors increased at the end of Wednesday and at the time of the Wednesday reporting period, where 1,305 institutional holders increased their position in Abbott Laboratories [NYSE:ABT] by around 58,589,978 shares. Additionally, 1,208 investors decreased positions by around 52,046,513 shares, while 381 investors held positions by with 1,196,324,909 shares. The mentioned changes placed institutional holdings at 1,306,961,400 shares, according to the latest SEC report filing. ABT stock had 283 new institutional investments in for a total of 7,409,494 shares, while 108 institutional investors sold positions of 4,329,528 shares during the same period.